403 ‒ Peptides: separating scientific promise from marketing hype
Peter Attia, MD — 403 ‒ Peptides: separating scientific promise from marketing hype
Channel: Peter Attia MD · Our label: Physician educator · Source: youtube.com/watch?v=Km_01CLEkYU
What this video covers
[music] » Welcome to a new episode of the Drive. Today we’re returning to peptides, a topic full of misinformation. So, we’re going to do a concise version um of the topic and make our original AMA and the show notes that accompanied them several months ago free to everyone. Uh peptides sit at this intersection of real science and rampant commercialization.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- Um peptides in this bucket, you know, look, it’s biologically plausible that they might work, uh but it’s not supported by any human clinical evidence.
- So, BPC 157 is is actually the case study and poster child for everything that should make you skeptical of a peptide.
- And BPC 157 itself doesn’t clearly match any known human gastrointestinal peptide or any other human protein.
And so, Peter, based on what you just said, what if someone says, you know, it is an unapproved peptide, but I got it from either a doctor, a compounding pharmacy, or a vendor that has third-party testing.
- So, I would say the answer is a doctor, a compounding pharmacy, or a third-party test may reduce some of the risks of using gray market peptides, but they don’t solve the fundamental problems.
- Roughly 100 peptide drugs are already approved, and about 150 more are in clinical trials, and 600 to 700 more are in preclinical development.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.